David M. Jackson
Business Development expert
PrimeraDx,
GenQual Corp
United States of America
Biography
Dr. David M. Jackson, Ph.D., Business Development at PrimeraDx, Inc. He was previously Senior Director, Companion Diagnostic Partnerships at QIAGEN, Inc. (formerly DxS). Dr. Jackson has extensive experience in companion diagnostic partnerships, business development,, and regulatory and commercialization strategy. He was previously VP Business Development & Licensing at DxS Ltd., which commercialized the therascreen® KRAS mutation assay (EU CE-IVD mark) as a companion diagnostic for colorectal carcinoma therapies Vectibix® and Erbitux®. He received his Ph.D. in Medicine and Physiology from the Boston University School of Medicine.
Research Interest
business development,, and regulatory and commercialization strategy.
